Coupled D dimer and fibrinogen levels during thrombolytic therapy of venous thromboembolism

State-of-the-Art Review: Usefulness of Laboratory Techniques for Evaluating Antithrombotic Efficacy of New Therapeutic Strategies

New drugs and new therapeutic strategies are being introduced for the prevention and the management of cardiovascular and thromboembolic disorders. Extensive clinical studies and large-scale epidemiological investigations are conducted to demonstrate the efficacy of these therapeutic approaches. Laboratory assays are invaluable tools for this exploration. We discuss how the new understanding concerning the regulation of the coagulolytic equilibrium offers novel investigation tools. Parameters reflecting the activities of new drugs targeted to their impact site and presenting few side effects are available. In addition to global clotting methods and chromogenic substrate-based assays, introduction of immunoassays has allowed measurement of most of the molecular markers of hemostatic activation. We recommend use of a panel of markers exploring the endothelial damage, the blood cell involvement, the early coagulant pathways' activation (XIIa and VIIa), the thrombin-formation pathways, the fibrin formation, and the evaluation of the global fibrinolytic capacity. When related to the clinical end points, all these laboratory assays offer useful and reliable monitoring of new drugs. They contribute to the establishment of new therapeutic strategies. Key Words: Hemostasis—Activation—Antithrombotic—Therapy— Laboratory monitoring.

Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE)

PURPOSE

We sought to assess prospectively whether higher levels of blood coagulation factors and inflammation markers are risk factors for venous thromboembolism.

SUBJECTS AND METHODS

In two pooled population-based cohort studies, we measured levels of factor VII, factor VIII, von Willebrand factor, fibrinogen, and C-reactive protein, and white blood cell count, in samples obtained from 19,237 adults with no baseline history of venous thromboembolism, cancer, or warfarin use. The endpoint was validated venous thromboembolism during follow-up (median, 7.8 years).

RESULTS

A total of 159 venous thromboembolism events occurred. Factor VIII and von Willebrand factor were linearly associated with increased risk of venous thromboembolism (P for trend <0.0001). As compared with those in the lowest quartile, the multivariate-adjusted hazard ratio (HR) of venous thromboembolism was 2.6 (95% confidence interval [CI]: 1.6 to 4.3) for factor VIII levels in the highest quartile and 3.8 (95% CI: 2.0 to 7.2) for the highest fifth percentile. For von Willebrand factor, the hazard ratios in middle-aged subjects were 4.6 (95% CI: 2.2 to 9.2) for the highest quartile and 7.6 (95% CI: 3.1 to 18) for the highest fifth percentile. Factor VII levels above the 95th percentile, as compared with the lowest quartile, also conveyed a higher risk of venous thromboembolism (HR = 2.4; 95% CI: 1.2 to 4.8). In contrast, there was no association of venous thromboembolism with fibrinogen or C-reactive protein levels, or white cell count.

CONCLUSIONS

In this prospective study, elevated factor VIII and von Willebrand factor levels were common, independent, and dose-dependent risk factors for venous thromboembolism, and an elevated factor VII level was a possible risk factor. Venous thromboembolism, unlike arterial disease, was not related to inflammatory markers.